This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

CIBIS-II

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

A randomised, double-blind, placebo-controlled trial of a novel beta-blocker, Carvedilol, in 1094 patients with symptomatic heart failure demonstrated a significant reduction in mortality and morbidity in the treatment group.

Patients had ejection fractions of <35%. Their current anti-failure treatment was not altered. Follow-up averaged 6.5 months.

The reduction in risk of death attributable to Carvedilol was 65% (95% confidence interval: 39-80%).

The reduction in risk of death or hospitalisation for cardiovascular causes attributable to Carvedilol was 38% (95% confidence interval: 18-53%).

The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II) also studied the use of a beta-blocker, bisoprolol, in patients with heart failure.

  • study involved 2647 patients who had an ejection fraction less than 35%. Patients were randomised to bisoprolol or placebo; all patients were on diuretics and ACE inhibitor
  • study revealed a 32% reduction in all-cause mortality in patients on bisoprolol

Reference:

  • Packer, M. et al. (1996). The effect of Carvedilol on morbidity and mortality in patients with chronic heart failure. New Engl. J. Med. 334, 1349-55. CIBIS-II investigators and Committee (1999). The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II). Lancet, 352, 9-13.

Create an account to add page annotations

Create a free account

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.